Darnitsa’s Strategy – Improvement of Compliance in Patients with Cardiovascular Diseases
One of the reasons of development of complications from cardiovascular disease in Ukraine is the low compliance to treatment. Only 56% of patients with arterial hypertension* comply with the recommended treatment regimen – these are the data of the survey among the participants of the 22nd National Congress of Cardiologists of Ukraine, the title partner of which was Darnitsa Pharmaceutical Company.
According to Ihor Nykyforchyn, Medical Director of Darnitsa, the healthcare system must develop and be aligned with the times, namely - ensure the multi-factor approach to compliance. “Treatment compliance is an important factor influencing the therapeutic consequences and the efficacy of the healthcare system in general. Darnitsa is one of the leaders of the cardiovascular market, we consistently work in the direction of improvement of treatment compliance for patients to achieve better therapeutic results and reduction of expenses on medical care”, he emphasizes. “Affordability of Darnitsa’s drugs for patients and convenience of their use due to fixed combinations make it possible to accurately comply with the treatment regimen recommended by the doctor”, Nykyforchyn notes.
Apart from supporting patients, Darnitsa maintains a dialogue with healthcare specialists on the importance of medical compliance. During the 22nd National Congress of Cardiologists of Ukraine, Darnitsa, together with the leading specialists in treatment of cardiovascular diseases in Ukraine, focused its attention on the issues of treatment standards and presented its view on the ways of solving the problem of arterial hypertension treatment compliance.
L.A. Mishchenko, Doctor of Medical Sciences, Head of the Department of Hypertensive Disease of the State Institution “National Scientific Center “M.D. Strazhesko Institute of Cardiology” of the National Academy of Medical Sciences of Ukraine, told about the peculiarities of selection of the optimal antihypertensive treatment for patients with arterial hypertension and coronary heart disease (00:53:44).
O.O. Matova, Candidate of Medical Sciences, presented the report “Daily Vaccination against Cardiovascular Complications – Clinical Case” (4:07:09) and told about “Reserves of Improvement of Blood Pressure Control: Focus on Treatment Compliance”.
N.Yu. Osovska, Doctor of Medical Sciences, provided the presentation “How to Prevent Uncontrolled Hypertension during the Pandemic” (03:53:30).
L.A. Mishchenko together with Endocrinologist Ya.A. Saienko also discussed “Prediabetes and Diabetes in Patients with Arterial Hypertension” (3:23:30).
During their report Prof. H.V. Zaichenko and Prof. M.M. Dolzhenko raised the issue of confidence in Ukrainian drugs, in particular, covered the concept of original and generic drugs and compliance with production requirements, bioequivalence studies using the example of standards adopted by Darnitsa Pharmaceutical Company (3:19:30).
Darnitsa has a strong portfolio of medicinal products for treatment of patients with cardiovascular diseases that are used by cardiologists and other medical specialists in their clinical practice. In 2021 the company extended its cardioportfolio with four new medicinal products with proven equivalence for treatment of cardiovascular diseases.
The 22nd National Congress of Cardiologists of Ukraine was held in Kyiv from September 21 to 24 and united Ukrainian and foreign professionals in the field.
* blood pressure equal to or greater than 140/90